Navigation Links
AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
Date:8/30/2007

WEST CHESTER, Ohio, Aug. 30 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the Thomas Weisel Partners 2007 Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 5th, at 9:45 a.m. ET.

A live Web cast and recording of the presentation will be available on the Investor Relations page of AtriCure's Web site at http://www.atricure.com. After the live Web cast, the presentation will remain available on AtriCure's Web site for 30 days.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices designed to create precise lesions, or scars, in cardiac and soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation clamps as a treatment alternative during open-heart surgical procedures to create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, leading cardiothoracic surgeons have described the AtriCure Isolator(R) bipolar ablation clamps as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5 million Americans and predisposes them to a five-fold increased risk of stroke.

The FDA has cleared the AtriCure I
'/>"/>

SOURCE AtriCure, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...ivanCotter Releases Results of Fourth Annual Physi...urvey, DETROIT, July 25 /PRNewswire/ -- Sullivan,...rth annual survey of physician on-call pay rates a...y Report. The survey report,with data from 132 he...ian,on-call pay practices and rates paid for 33 ph...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begin...l/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ...ced today that its subsidiary has commenced commer...psules USP product in the 40mg,strength from its D...on,with the launch, Watson has 180 days of marketi...
(Date:7/25/2008)... McKesson Corporation Executive, Robert J. Reilly,...re/ -- Aethon Inc.,( http://www.aethon.com ), the ...supply chain logistics, today announced that Rober...President -- Chief Financial Officer., Reilly, wh...ger for,McKesson Corporation,s Specialty Pharmacy ...
(Date:7/25/2008)...STON, July 25 /PRNewswire/ -- The Elekta Family of...er treatment solutions at the 2008,American Associ...ing,demonstrating how the joint forces of Elekta,...on therapy planning and delivery solutions that,st...experience for,patients, as well as enhance clinic...
Breaking Medicine News(10 mins):Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3
...yroid hormone plays a major role in the developmen...al levels of the natural hormone can be toxic to a... high levels of thyroid // hormone and still be no... these affected women may carry fetuses that have ...
...ostate cancer is the second-leading cause of cance...ar. The lifetime risk of being diagnosed, one in s... cancer in women. // A new study shows the rate of... velocity, before prostate cancer diagnosis is a m...
...w research shows a significant improvement in trea...led stage I seminoma. Stage I seminoma is typicall...y radiation. Radiation, though, poses a risk of de...n up to 20 years later. Researchers randomized mor...
...tox commonly used for cosmetic purposes to erase t...are using it for medical reasons.//Now, the toxin ...s gastroparesis. Gastroparesis is where there is d... meal. It may be for solid food or for liquids, wh...
Other Medicine News:
(Date:7/23/2008)...ire/ -- Sound Pharmaceuticals (SPI) has filed,an I...or the clinical,testing of a proprietary formulati...nduced hearing loss or ototoxicity. The oral capsu... advanced stage lung cancer,and head and neck canc...,This marks the second development program for SPI...
(Date:7/23/2008)...RNewswire/ -- InCode BioPharmaceutics, Inc.,an em...preclinical test,results demonstrating the utility...ent of the rare chronic blood disorder paroxysmal ...ts will be presented at the XXII,International Com...28,2008., The only treatment currently available...
(Date:7/22/2008)... from a multi-center 293-patient European, trial ...ange Symbol: CYT, MONTREAL, July 22 /PRNewswire-F...bal leader in cryotherapy products to treat cardia...usly presented from three,European study centers u...were published earlier today in the Journal of the...
(Date:7/22/2008)...lity and Efficacy of Treating Patients with ...CISCO, and YONGIN-SI, South Korea, July 22 /PRNews...awa, Ontario), and its South,Korean partner Green ...rom,a Phase I clinical trial of its first-in-class... was well-tolerated and resulted in clear,anti-can...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Standard Glucose Test May Be Wrong One for Obese Children 21873 1Standard Glucose Test May Be Wrong One for Obese Children 21873 2Some patients may not need insulin for long term control of type 2 diabetes 21870 1Some patients may not need insulin for long term control of type 2 diabetes 21870 2UT Southwestern researchers create molecule that nudges nerve stem cells to mature 3639 1UT Southwestern researchers create molecule that nudges nerve stem cells to mature 3639 2UT Southwestern researchers create molecule that nudges nerve stem cells to mature 3639 3A Health Gift for Men on Fathers Day 21866 1A Health Gift for Men on Fathers Day 21866 2
... years; focus moves to,House, WASHINGTON, May 09, ...verwhelmingly passed significant prescription drug...ration more power to deal,with unsafe medicines on...e House, where a strong bill has been introduced b...be congratulated for passing reforms to,ensure pat...
... and a Health Conscious,Public?, WASHINGTON, April...Drug Administration (FDA) must adapt to the most s...ommissioner Andrew von,Eschenbach told attendees a...nference April 12 in Bethesda, Md. , FDA must find...cial and personnel resources to deal with the chal...
Other Medicine Technology:Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type,Disasters; House Urged to Act on Strong Drug Safety Bill 2Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type,Disasters; House Urged to Act on Strong Drug Safety Bill 3Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type,Disasters; House Urged to Act on Strong Drug Safety Bill 4FDLI 50th Annual Meeting Heralds New ERA in Healthcare Innovations,FDA Regulations 2
Significantly more compact and tidier in overall looks yet retain many of the excellent features of the more comprehensive Haag type systems., ,Filters include Cobalt blue; green (red free); neut
An easy to use uncomplicated ophthalmoscope.
Comes complete in its own carrying case. There are 24 lenses, 13mm diameter -6D to +6D in 0.5D steps. Mounted in tough, yet light alloy frame.
Halberg Trial Clips have become a required addition to every refractive stand., ,These useful and inexpensive clips may be fitted over your patient's spectacle frame. Each cell has space for thre
Medicine Products: